A recent study suggests that people who discontinue popular GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds far faster than those who stop conventional lifestyle regimens.
Published data in a major health publication demonstrates that while overweight individuals frequently drop substantial amounts of their body weight while using the jabs, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Users buying such drugs need to be informed of the risk of quick rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.
That rate of regain suggests a return to starting weight within about one and a half years.
Weighing Approaches
The analysis, which reviewed 37 of studies involving thousands of patients, compared the outcomes of the injectable medications with older methods.
The team point out that individuals who lose weight through dieting generally see a less rapid creep back—around 100 grams monthly—once they finish.
Understanding the Quick Regain
Experts believe the way of the jabs explains the accelerated weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating much more probable."
An Ongoing Issue?
Health authorities advise the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, considering the high risk of relapse, the therapy might need to be life-long.
This opinion is supported by drug manufacturers, who state that the findings "underscore the persistent character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Experiences
People who have stopped the medication explain a intense return of appetite.
"I experienced something activating and you're instantly extremely hungry," recalled a patient.
This difficulty is worsened if individuals have not established lasting dietary or behavioural modifications during treatment.
Significant Use
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Use is greater among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while these medications are potent agents for weight loss, they are not a permanent solution and lasting health benefits likely depends on integrated behavioural changes.
